Response to treatment in NMOSD: the Australasian experience-Reference-Cited by-同舟云学术

Response to treatment in NMOSD: the Australasian experience

Published:2021-11 Issue: Volume: Page:103408
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Clarke Laura,Bukhari Wajih,O'Gorman Cullen M.,Khalilidehkordi Elham,Arnett Simon,Woodhall Mark,Prain Kerri M.,Parratt John D.E.,Barnett Michael H.,Marriott Mark P.,McCombe Pamela A.,Sutton Ian,Boggild Mike,Brownlee Wallace,Carroll William M.,Hodgkinson Suzanne,Macdonell Richard A.L.,Mason Deborah F.,Pereira Jennifer,Slee Mark,Das Chandi,Henderson Andrew P.D.,Kermode Allan G.,Lechner-Scott Jeannette,Waters Patrick,Sun Jing,Broadley Simon A.

Funder

Multiple Sclerosis Research Australia

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference31 articles.

1. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series;Azzopardi;J. Neurol.,2016

2. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography;Bennett;Mult. Scler.,2015

3. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis;Borisow;Front. Neurol.,2018

4. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo;Bradl;Ann. Neurol.,2009

5. The clinical profile of NMOSD in Australia and New Zealand;Bukhari;J. Neurol.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04